Although several mGluR2/3 antagonists/NAMs show great therapeutic potential for the treatment of depression in preclinical investigations, the outcomes of clinical trials were not particularly encouraging (Umbricht et al. 2020). This evidence concerns the gene GRM2 and depressive symptom measurement.